Anti-Human CD257 (BAFF) (Tabalumab) - Fc Muted™

Contact us
Leinco Technologies
Product Code: LEI-LT1405
Product Group: Primary Antibodies
CodeSizePrice
LEI-LT1405-CustomCustomEnquire
Quantity:
LEI-LT1405-500ug500 ug£408.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Antibody Isotype: Human IgG1κ
Antibody Clonality: Monoclonal
Antibody Clone: Tabalumab
Regulatory Status: RUO
Target Species:
  • Cynomolgus Monkey
  • Human
  • Rabbit
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Flow Cytometry
  • Functional Study
  • Immunofluorescence (IF)
  • Immunoprecipitation (IP)
  • Neutralisation
  • Western Blot (WB)
Shipping:
2 - 8°C Wet Ice
Storage:
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C.?Avoid Repeated Freeze Thaw Cycles.

Further Information

Antigen Distribution:
BAFF is expressed on various cell types including monocytes, dendritic cells and bone marrow stromal cells.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Original antibody was raised against soluble human BAFF.
Long Description:
Tabalumab is a human monoclonal anti-B-cell activating factor (BAFF) antibody intended for the treatment of autoimmune diseases and B cell malignancies.1 BAFF is a membrane-bound, type II transmembrane protein that belongs to the tumor necrosis factor (TNF) ligand family and is the ligand for BR3, TACI, and BCMA. BAFF is an immunostimulant necessary for maintaining normal immunity. This cytokine has also been shown to play an important role in the proliferation and differentiation of B cells. An inadequate level of BAFF leads to immunodeficiency whilst an elevated level of BAFF causes unusually high antibody production that results in the development of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Additionally, BAFF has been found in renal transplant biopsies with acute rejection.2 Furthermore, BAFF may be a mediator of food-related inflammation, and is associated with multiple dietary ailments including celiac disease, insulin resistance, diabetes, and obesity.3 Interestingly, it is suspected that BAFF may be involved in non-IgE-mediated reactions because there is no known correlation between BAFF and IgE.4 More research is needed to unlock the enormous therapeutic potential for BAFF antagonists. This cost-effective, research-grade Anti-Human CD257 (BAFF) (Tabalumab) utilizes the same variable regions from the therapeutic antibody Tabalumab making it ideal for research projects.
NCBI Gene:
10673
Purity:
?95% monomer by analytical SEC, ?98% monomer by analytical SEC
Target:
BAFF

References

1. Manetta, J. et al. (2014) J Inflamm Res. 7: 121?131 2. Clatworthy, MR. et al. (2013) Transplantation. 96(4): 413?420. 3. Lied, GA. and Berstad, A. (2011) Scand J Immunol. 73(1):1-7. 4. B?chler, JR. and Cano, MN. (1986) Jpn Heart J. 27(1):117-22.